Synthetic sideromycins (skepticism and optimism): selective generation of either broad or narrow spectrum Gramnegative antibiotics

BioMetals

Volumn 32, Issue 3, 2019, Pages 425-451

  Lin, Yun Ming ^a   Ghosh, Manuka ^a   Miller, Patricia A ^a   Möllmann, Ute ^a   Miller, Marvin J ^b  

^a Rosetree Corporate Center   (United States)

^b UNIVERSITY OF NOTRE DAME   (United States)

Author keywords

Antibiotic conjugates; In vivo tolerability and efficacy; Iron transport mediated delivery; Resistant bacteria; Sideromycins; Siderophores; Trojan horse

Indexed keywords

ANTIINFECTIVE AGENT; FERROUS ION; PEPTIDE; SIDEROMYCINS;

CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECT; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; MICROBIAL SENSITIVITY TEST; MULTIDRUG RESISTANCE; SYNTHESIS;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FERROUS COMPOUNDS; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; MICROBIAL SENSITIVITY TESTS; MOLECULAR STRUCTURE; PEPTIDES;

EID: 85064230561     PISSN: 09660844     EISSN: 15728773     Source Type: Journal    
DOI: 10.1007/s10534-019-00192-6     Document Type: Article

References (100)

1. Abergel RJ, Zawadzka AM, Hoette TM, Raymond KN (2009) Enzymatic hydrolysis of trilactone siderophores: where chiral recognition occurs in enterobactin and bacillibactin iron transport. J Am Chem Soc 131:12682–12692
2. Akinobu I, Nishikawa T, Matsumoto S, Yoshizawa H, Sato T, Nakamura R, Tsuji M, Yamano Y (2016) Siderophore cephalosporin cefiderocol utilizes ferric iron transporter systems for antibacterial activity against Pseudomonas aeruginosa. Antimicrob Agents Chemother 60:7396–7401
3. Barbachyn MR, Tuominen TC (1990) Synthesis and structureactivity relationships of monocarbams leading to U-78608. J Antibiot 43:1199–1202
4. Benz G, Schroder T, Kurz J, Wünsche C, Karl W, Steffens G, Pfitzner J, Schmidt D (1982) Constitution of the deferriform of the albomhcins d1, d2 and e. Angew Chem Int Ed Engl 21:527–528
5. Bluhm ME, Kim SS, Dertz EA, Raymond KN (2002) Corynebactin and enterobactin: related siderophores of opposite chirality. J Am Chem Soc 124:2436–2437
6. Boyd DB, Eigenbrot C, Indelicato JM, Miller MJ, Pasini CE, Woulfe SR (1987) Heteroatom activated ß-lactam antibiotics: considerations of differences in biological activity of [[3(S)-(acylamino)-2-oxo-1-azetidinyl]-oxy]acetic acids (Oxamazins) and the corresponding sulfur analogues (Thiamazins). J Med Chem 30:528–536
7. Braun V, Pramanik A, Gwinner T, Koberle M, Bohn E (2009) Sideromycins: tool and antibiotics. Biometals 22:3–13
8. Breuer H, Bisacchi GS, Drossard J-M, Ermann P, Koster WH, Kronenthal D, Juester P, Linder KR, Straub H, Treuner UD, Zahler R (1985) Structure-activity relationships among sulfonylaminocarbonyl activated mono bactams leading to SQ-83,360. Program and Abstracts of the 25th Interscience Conference on Antimicrobial Agents and Chemotherapy, No 371, p. 158, Minneapolis, MN, Sept 29-Oct 2, 1985
9. Brochu A, Brochu N, Nicas TI, Parr TR, Minnick AA, Dolence EK, McKee JA, Miller MJ, Lavoie MC, Malouin F (1992) Modes of action and inhibitory activities of new siderophore-b-lactam conjugates that use specific iron uptake pathways for entry into bacteria. Antimicrob Agents Chemother 36:2166–2175
10. Budzikiewicz H (2001) Siderophore-antibiotic conjugates used as trojan horses aginst Pseudomonas aeruginosa. Curr Top Med Chem 1:73–82
11. Bush K, Freudenberger JS, Sykes RB (1982) Interaction of azthreonam and related monobactams with b-lactamases from Gram-negative bacteria. Antimicrob Agents Chemother 22:414–420
12. Bush K, Courvalin P, Dantas G, Davies J, Eisenstein B, Huovinen P, Jacoby GA, Kishony R, Kreiswirth BN, Kutter E, Lerner SA, Levy S, Lewis K, Lomovskaya O, Miller JH, Mobashery S, Piddock LJ, Projan S, Thomas CM, Tomasz A, Tulkens PM, Walsh TR, Watson JD, Witkowski J, Witte W, Wright G, Yeh P, Zgurskaya HI (2011) Tackling antibiotic resistance. Nat Rev Microbiol 9:894–896
13. Calvopiña K, Umland K-D, Rydzik AM, Hinchliffe P, Brem J, Spencer J, Schofield CJ, Avisona MB (2016) Sideromimic modification of lactivicin dramatically increases potency against extensively drug-resistant Stenotrophomonas maltophilia clinical isolates. Antimicrob Agents Chemother 60:4170–4175
14. Carosso S, Liu R, Miller PA, Hecker SJ, Glinka T, Miller MJ (2017) Methodology for monobactam diversification: syntheses and studies of 4-thiomethyl substituted b-lactams with activity against Gram-negative bacteria, including carbapenemase producing acinetobacter baumannii. J Med Chem 60:8933–8944
15. Cimarusti CM, Sykes RB (1984) Monocyclic b-lactam antibiotics. Med Res Rev 4:17–20
16. McKenna M https://www.wired.com/2014/12/oneill-rpt-amr/ (accessed January 7, 2019)
17. Crosa JH, Mey AR, Payne SM (2004) Iron transport in bacteria. ASM Press, Washington, DC. ISBN 1-55581-292-9
18. Cuıv PO, Clarke P, O’Connell M (2006) Identification and characterization of an iron-regulated gene, chtA, required for the utilization of the xenosiderophores aerobactin, rhizobactin 1021 and schizokinen by Pseudomonas aeruginosa. Microbiology 152:945–954
19. Cusnir R, Imberti C, Hider RC, Blower PJ, Ma MT (2017) Hydroxypyridinone chelators: from iron scavenging to radiopharmaceuticals for pet imaging with gallium-68. Int J Mol Sci 18:116–139
20. Dayan I, Libman J, Agi Y, Shanzer A (1993) Chiral siderophore analogs: ferrichrome. Inorg Chem 32:1467–1475
21. Dolence EK, Minnick AA, Miller MJ (1990) N5-acetyl-N5-hydroxy-L-ornithine-derived siderophore-carbacephlosporin b-lactam conjugates: iron transport mediated drug delivery. J Med Chem 33:461–464
22. Dolence EK, Lin C-E, Miller MJ (1991a) Synthesis and siderophore activity of albomycin-like peptides derived from N5-Acetyl-N5-hydroxy-L-orinithine. J Med Chem 34:956–968
23. Dolence EK, Minnick AA, Lin C-E, Miller MJ (1991b) Synthesis and siderophore and antibacterial activity of N5-Acetyl-N5-hydroxy-L-ornithine-derived siderophore-blactam conjugates: iron-transport-mediated drug delivery. J Med Chem 34:968–978
24. Dong L, Roosenberg JM, Miller MJ (2002) Total synthesis of desferrisalmycin B. J Am Chem Soc 124:15001–15005
25. Fisher JF, Mobashery S (2016) Endless resistance. Endless antibiotics? Med Chem Comm 7:37–49
26. Flanagan ME, Brickner SJ, Lall M, Casavant J, Deschenes L, Finegan SM, George DM, Granskog K, Hardink JR, Huband MD, Hoang T, Lamb L, Marra A, Mitton-Fry M, Mueller JP, Mullins LM, Noe MC, O’Donnell JP, Pattavina D, Penzien JP, Schuff BP, Sun S, Whipple DA, Young J, Gootz TD (2011) Preparation, Gram-negative antibacterial activity, and hydrolytic stability of novel siderophoreconjugated monocarbam diols. ACS Med Chem Lett 2:385–390
27. Furst AL, Francis MB (2019) Impedance-based detection of bacteria. Chem Rev 119:700–726
28. Gause GF (1955) Recent studies on albomycin, a new antibiotic. BMJ 2:1177
29. Ghosh M, Miller MJ (1996) Synthesis and In vitro antibacterial activity of spermidine-based mixed catechol-and hydroxamate-containing siderophore-vancomycin conjugates. Bioorg Med Chem 4:43–48
30. Ghosh A, Ghosh M, Niu C, Malouin F, Möllmann U, Miller MJ (1996) Iron transport-mediated drug delivery using mixedligand siderophore-b-lactam conjugates. Chem Biol 3:1011–1019
31. Ghosh M, Miller PA, Möllmann U, Claypool WD, Schroeder VA, Wolter WR, Suckhow M, Yu H, Li S, Huang W, Zajicek J, Miller MJ (2017) Targeted antibiotic delivery: selective siderophore conjugation with daptomycin confers potent activity against multi-drug resistant Acinetobacter baumannii both in vitro and in vivo. J Med Chem 60:4577–4583
32. Ghosh M, Lin Y-M, Miller PA, Möllmann U, Boggess WC, Miller MJ (2018) Siderophore conjugates of daptomycin are potent inhibitors of carbapenem resistant strains of Acinetobacter baumannii. ACS Infect Dis 4:1529–1535
33. Han S, Zaniewski RP, Marr ES, Lacey BM, Tomaras AP, Evdokimov A, Miller RJ, Shanmugasundaram V (2002) Structural basis for effectiveness of siderophore-conjugated monocarbams against clinically relevant strains of pseudomonas. PNAS 107:22002–22007
34. Heinisch L, Gebhardt P, Heidersbach R, Reissbrodt R, Möllmann U (2002a) New synthetic catecholate-type siderophores with triamine backbone. Biometals 15:133–144
35. Heinisch L, Wittmann S, Stoiber T, Berg A, Ankel-Fuchs D, Möllmann U (2002b) Highly antibacterial active aminoacyl penicillin conjugates with acylated bis-catecholate siderophores based on secondary diamino acids and related compounds. J Med Chem 45:3032–3040
36. Hennard C, Truong QC, Desnottes JF, Paris JM, Moreau NJ, Abdallah MA (2001) Synthesis and activities of pyoverdinquinolone adducts: a prospective approach to a specific therapy against Pseudomonas aeruginosa. J Med Chem 44:2139–2151
37. Hider RC, Kong X (2010) Chemistry and biology of siderophores. Nat Prod Rep 27:637–657 https://www.bbc.com/news/health-45983320 (accessed January 15, 2019)
38. Hu J, Ghosh M, MillerMJ Bohn P (2019) Whole-cell biosensing by siderophore-based molecular recognition and localized surface plasmon resonance. Anal Methods 11:296–302
39. Ito A, Kohira N, Bouchillon SK, West J, Rittenhouse S, Sader HS, Rhomberg PR, Jones RN, Yoshizawa H, Nakamura R, Tsuji M, Yamano Y (2016) In vitro antimicrobial activity of S-649266, a catechol substituted siderophore cephalosporin, when tested against non-fermenting gram-negative bacteria. J Antimicrob Chemother 71:670–677
40. Ito-Horiyama T, Ishii Y, Ito A, Sato T, Nakamura R, Fukuhara N, Tsuji M, Yamano Y, Yamaguchi K, Tateda K (2016) Stability of novel siderophore cephalosporin S-649266 against clinically relevant carbapenemases. Antimicrob Agents Chemother 60:4384–4386
41. Ji C, Miller MJ (2012) Chemical syntheses and in vitro antibacterial activity of two desferrioxamine B-ciprofloxacin conjugates with potential esterase and phosphatase triggered drug release linkers. Bioorg Med Chem 20:3828–3836
42. Ji C, Miller PA, Miller MJ (2012) Iron transport-mediated drug delivery: practical syntheses and in vitro antibacterial studies of Tris-catecholate siderophore-aminopenicillin conjugates reveals selectively potent anti-pseudomonal activity. J Am Chem Soc 134:9898–9901
43. Ji C, Miller PA, Miller MJ (2015) Syntheses and antibacterial activity of N-acylated ciprofloxacin derivatives based on the trimethyl lock. ACS Med Chem Lett. 6:707–710
44. Katsu K, Kitoh K, Inoue M, Mitsuhashi S (1982) In vitro antibacterial activity of E-0702, a new semisynthetic cephalosporin. Antimicrob Agents Chemother 22:181–185
45. Kinzel O, Tappe R, Gerus I, Budzikiewicz H (1998) The synthesis and antibacterial activity of two pyoverdin-ampicillin conjugates, entering Pseudomonas aeruginosa via the pyoverdin-mediated iron uptake pathway. J Antibiot 51:499–507
46. Knüsel F, Nüesch J (1965) Mechanism of action of sideromycins. Nature 206:674–676
47. Kohira N, West J, Ito A, Ito-Horiyama T, Nakamura R, Sato T, Rittenhouse S, Tsuji M, Yamano Y (2016) In vitro antimicrobial activity of siderophore cephalosporin S-649266 against enterobacteriaceae clinical isolates including carbapenem-resistant strains. Antimicrob Agents Chemother 60:729–734
48. Lax E (2004) The mold in Dr. Florey’s coat The story of the penicillin miracle. Henry Holt and Co., New York, p 307
49. Liu R, Miller PA, Vakulenko SB, Stewart NK, Boggess WC, Miller MJ (2018) A synthetic dual drug sideromycin induces gram-negative bacteria to commit suicide with a gram-positive antibiotic. J Med Chem 61:3845–3854
50. Macheboeuf P, Fischer DS, Brown T Jr, Zervosen A, Luxen A, Joris B, Dessen A, Schofield CJ (2007) Structural and mechanistic basis of penicillin-binding protein inhibition by lactivicins. Nat Chem Biol 3:565–569
51. Maejima T, Inoue M, Mitsuhashi S (1991) The role of cefotaxime in the treatment of surgical infection. Antimicrob Agents Chemother 52:104–110
52. McKee JA, Sharma SK, Miller MJ (1991) Iron transport mediated drug delivery systems: synthesis and antibacterial activity of spermidine-and lysine-based siderophore-blactam conjugates. Bioconj Chem 2:281–291
53. McPherson CJ, Aschenbrenner LM, Lacey BM, Gahnoe KC, Lemmon MM, Finegan SM, Adakamalla B, O’Donnell JP, Mueller JP, Tomaras AP (2012) Clinically relevant gramnegative resistance mechanisms have no effect on the efficacy of MC-1, a novel siderophore-conjugated monocarbam. Antimicrob Agents Chemother 56:6334–6342
54. Miethke M, Marahiel M (2007) Siderophore-based iron acquisition and pathogen control. Microbiol Mol Biol Rev 71:413–451
55. Miller MJ (1989) Syntheses and therapeutic potential of hydroxamic acid based siderophores and analogues. Chem Rev 89:1563–1579
56. Miller MJ, Malouin F (1993) Microbial iron chelators as drug delivery agents: the rational design and synthesis of siderophore-drug conjugates. Acc Chem Res 26:241–249
57. Miller MJ, Malouin F (1994) Siderophore-mediated drug delivery: the design, synthesis, and study of siderophoreantibiotic and antifungal conjugates. In: Bergeron RJ, Brittenham GM (eds) The development of iron chelators for clinical use. CRC, Boca Raton, pp 275–306
58. Miller MJ, Zhu H, Xu Y, Wu C, Walz AJ, Vergne A, Moraski G, Minnick AA, McKee-Dolence J, Dolence EK, Hu J, Fennell K, Franzblau S, Malouin F, Möllmann U (2009) Utilization of microbial iron assimilation processes for the development of new antibiotics and inspiration for the design of new anticancer agents. Biometals 22:61–75
59. Miller MJ, Walz AJ, Zhu H, Wu C, Moraski G, Möllmann U, Tristani EM, Crumbliss AL, Ferdig MT, Checkley L, Edwards RL, Boshoff HI (2011) J Am Chem Soc 133:2076–2079
60. Minnick AA, McKee JA, Dolence EK, Miller MJ (1992) Iron transport-mediated antibacterial activity of and development of resistance to hydroxamate and catechol siderophore-carbacephalosporin conjugates. Antimicrob Agents Chemother 36:840–850
61. Mislin GL, Schalk IJ (2014) Siderophore-dependent iron uptake systems as gates for antibiotic Trojan horse strategies against Pseudomonas aeruginosa. Metallomics 6:408–420
62. Mochizuki H, Yamada H, Oikawa Y, Murakami K, Ishiguro J, Kosuzume H, Aizawa N, Mochida E (1988) Bactericidal activity of M1469 enhanced in low-iron environments. Antimicrob Agents Chemother 32:1648–1654
63. Möllmann U, Heinisch L, Bauernfeind A, Köhler T, AnkelFuchs D (2009) Siderophores as drug delivery agents: application of the ‘‘Trojan Horse’’ strategy. Biometals 22:615–624
64. Nakagawa S, Sanada M, Matsuda K, Hashizume T, Asahi Y, Ushijima R, Ohtake N, Tanaka N (1989) In vitro and in vivo antibacterial activities of BO-1341, a new antipseudomonal cephalosporin. Antimicrob Agents Chemother 33:1423–1427
65. Neilands JB (1995) Siderophores: structure and function of microbial iron transport compounds. J Biol Chem 270:26723–26726
66. Neumann W, Sassone-Corsi M, Raffatellu M, Nolan EM (2018) Esterase-catalyzed siderophore hydrolysis activates an enterobactin-ciprofloxacin conjugate and confers targeted antibacterial activity. J Am Chem Soc 140:5193–5201
67. Nozaki Y, Katayama N, Harada S, Ono H, Okazaki H (1989) Lactivicin, a naturally occurring non-b-lactam antibiotic having b-lactam like action: biological activities and mode of action. J Antibiot (Tokyo) 42:84–93
68. Ohi N, Aoki B, Shinozaki T, Moro K, Noto T, Nehashi T, Okazaki H, Matsunaga I (1986) Semisynthetic b-lactam antibiotics I. Synthesis and antibacterial activity of new ureidopenicillin derivatives having catechol moieties. J Antibiot 39:230–241
69. Page MG, Dantier C, Desarbre E (2010) In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram negative bacilli. Antimicrob Agents Chemother 54:2291–2302
70. Pogliano J, Pogliano N, Silverman JA (2012) Daptomycinmediated reorganization of membrane architecture causes mislocalization of essential cell division proteins. J Bacteriol 194:4494–4504
71. Poole K, McKay GA (2003) Iron acquisition and its control in Pseudomonas aeruginosa: many roads lead to Rome. Front Biosci 8:661–686
72. Portsmouth S, van Veenhuyzen D, Echols R, Machida M, Ferreira JCA, Ariyasu M, Tenke P, Nagata TD (2018) Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial. The Lancet Infect Diseases 18:1319–1328
73. Pramanik A, Braun V (2006) Albomycin uptake via a ferric hydroxamate transport system of Streptococcus pneumoniae R6. J Bacteriol 188:3878–3886
74. Rex JH (2014) ND4BB: addressing the antimicrobial resistance crisis. Nat Rev Microbiol 12:231–232
75. Rivault F, Liebert C, Burger A, Hoegy F, Abdallah MA, Schalk IJ, Mislin GLA (2007) Synthesis of pyochelin-norfloxacin conjugates. Bioorg Med Chem Lett 17:640–644
76. Sackmann W, Reusser P, Neipp L, Dradolfer F, Gross F (1962) Ferrimycin A, a new iron-containing antibiotic. Antib Chemo 12:34–38
77. Schalk IJ (2018a) A trojan-horse strategy including a bacterial suicide action for the efficient use of a specific gram-positive antibiotic on gram-negative bacteria. J Med Chem 61:3842–3844
78. Schalk IJ (2018b) Siderophore antibiotic conjugates: exploiting iron uptake to deliver drugs into bacteria. Clin Microbiol Infect 24:801–802
79. Schalk IJ, Guillon L (2013) Fate of ferrisiderophores after import across bacterial outer membranes: different iron release strategies are observed in the cytoplasm or periplasm depending on the siderophore pathways. Amino Acids 5:1267–1277
80. Schnabelrauch M, Wittmann S, Rahn K, Möllman U, Reissbrodt R, Heinisch L (2000) New synthetic catecholate-type siderophores based on amino acids and dipeptides. Biometals 13:333–348
81. Shanzer A, Libman J, Yakirevitch P, Hadar Y, Chen Y, Jurkevitch E (1993) Siderophore-mediated microbial iron(III) uptake: an exercise in chiral recognition. Chirality 5:359–365
82. Snow GA (1970) Mycobactins: iron-chelating growth factors from mycobacteria. Bacteriol Rev 34:99–125
83. Starr J, Brown MF, Aschenbrenner L, Caspers N, Che Y, Gerstenberger BS, Huband M, Knafels JD, Lemmon MM, Li C, McCurdy SP, McElroy E, Rauckhorst MR, Tomaras AP, Young JA, Zaniewski RP, Shanmu-Gasundaram V, Han S (2014) Siderophore receptor-mediated uptake of lactivicin analogues in Gram-negative bacteria. J Med Chem 57:3845–3855
84. Tacconelli E (2019) Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. www.who.int/medicines/publications/WHO-PPL-Short_Summary_25Feb-ET_NM_WHO.pdf (accessed February 8, 2019)
85. Tamura N, Matsushita Y, Kawano Y, Yoshioka K (1990) Synthesis and antibacterial activity of lactivicin derivatives. Chem Pharm Bull (Tokyo) 38:116–122
86. Taylor SD, Palmer M (2016) The action mechanism of daptomycin. Bioorg Med Chem 24:6253–6268
87. Tomaras AP, Crandon JL, McPherson CJ, Nicolau P (2015) Potentiation of antibacterial activity of the MB-1 siderophore-monobactam conjugate using an efflux pump inhibitor. Antimicrob Agents Chemother 59:2439–2442
88. Vertesy L, Aretz W, Fehlhabe HW, Kogler H (1995) 3.Salmycin A-D, Antibiotika aus Streptomyces violaceus, DSM 8286, mit Siderophor-Aminoglycosid-Struktur. Helv Chim Acta 78:46–60
89. Walsh CT, Wencewicz TA (2016) Antibiotics: challenges, mechanisms, opportunities. ASM Press, Washington, DC
90. Watanabe NA, Nagasu T, Katsu K, Kitoh K (1987) E-0702, a new cephalosporin, is incorporated into Escherichia coli cells via the tonB-dependent iron transport system. Antimicrob Agents Chemother 31:497–504
91. Wencewicz TA, Miller MJ (2013) Biscatecholate–monohydroxamate mixed ligand siderophore–carbacephalosporin conjugates are selective sideromycin antibiotics that target acinetobacter baumannii. J Med Chem 56:4044–4052
92. Wencewicz TA, Miller MJ (2017) Sideromycins as pathogen targeted antibiotics. Top Med Chem 26:151–184
93. Wencewicz TA, Möllmann U, Long TE, Miller MJ (2009) Is drug release necessary for antimicrobial activity of siderophore-drug conjugates? Syntheses and biological studies of the naturally occurring salmycin ‘‘Trojan Horse’’ antibiotics and synthetic desferridanoxamine-antibiotic conjugates. Biometals 22:633–648
94. Winkelmann G, Braun V (1981) Stereoselective recognition of ferrichrome by fungi and bacteria. FEMS Microbiol Lett 11:237–241
95. Wittmann S, Schnabelrauch M, Scherlitz-Hofmann I, Möllmann U, Ankel-Fuchs D, Heinisch L (2002) New synthetic siderophores and their b-lactam conjugates based on diamino acids and dipeptides. Bioorg Med Chem 10:1659–1670
96. Wittmann S, Heinisch L, Scherlitz-Hofmann I, Stoiber T, Ankel-Fuchs D, Möllmann U (2004) Catecholates and mixed catecholate hydroxamates as artificial siderophores for mycobacteria. Biometals 17:53–64
97. Zahner H, Diddens H, Keller-Schierlein W, Nageli HU (1977) Some experiments with semisynthetic sideromycins. Jpn J Antibiot 30:201–206
98. Zheng NT, Nolan EM (2014) Enterobactin-mediated delivery of b-lactam antibiotics enhances antibacterial activity against pathogenic Escherichia coli. J Am Chem Soc 136:9677–9691
99. Zheng T, Nolan EM (2015) Evaluation of (acyloxy)alkyl ester linkers for antibiotic release from siderophore–antibiotic conjugates. Bioorg Med Chem Lett 25:4987–4991
100. Zheng T, Bullock JL, Nolan EM (2012) Siderophore-mediated cargo delivery to the cytoplasm of escherichia coli and Pseudomonas aeruginosa: syntheses of monofunctionalized enterobactin scaffolds and evaluation of enterobactincargo conjugate uptake. J Am Chem Soc 134:18388–18400